Discover how cell-based therapy is emerging as a promising treatment option for COPD patients. Learn about its benefits, ...

Glenmark Pharma launches Nebzmart GFB & Airz FB Smartules, a fixed-dose triple therapy for COPD. Improves lung function & ...

Glenmark Pharmaceuticals has launched a groundbreaking nebulised triple therapy for COPD. This single, easy-to-use treatment ...

The company has launched Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, world's first nebulised, fixed-dose ...

Glenmark Pharmaceuticals added 1.75% after the company announced launch of Nebzmart GFB Smartules and Glenmark Airz FB Smartules, the world's first nebulized, fixed-dose triple therapy for Chronic ...

The GOLD COPD Update 2026 provides updated guidance on case-finding, disease activity, exacerbation management.

The global inhaled therapy in respiratory disease market size was valued at USD 11.58 billion in 2024 and is predicted to hit around USD 16.22 billion by 2034, rising at a 3.44% CAGR, a study ...

The 2026 version of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy report has been published. Key ...

Early detection and innovative biologic treatment can prevent hospitalizations, improve quality of life, and extend the ...

Pulmonologists warn India faces a rising COPD and chronic lung disease crisis, driven by severe air pollution. Experts urge ...

Whenever we think of difficulty in breathing, the first image that comes to mind is often the dramatic scenes shown in movies ...